# SIGA catalysts: SIGA TECHNOLOGIES INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/siga/catalysts

> SIGA TECHNOLOGIES INC (SIGA) has 2 upcoming catalysts. The next is the TPOXX® (tecovirimat) primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | SIGA TECHNOLOGIES INC |
| Ticker | SIGA (Nasdaq) |
| SEC CIK | 1010086 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/siga |

## Cash runway

Cash $116.4M as of 2026-09-30; quarterly burn $1.2M; about 295.5 months of runway at that rate (XBRL company facts, accession 0001437749-26-035925).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 13, 2018 | [TPOXX® (tecovirimat) FDA approval](https://sec-api.dev/pdufa/tecovirimat) | SIGA |  | completed, approved | "NDA208627 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180713, review_priority PRIORITY; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22)) |
| November 23, 2021 | [TPOXX® (tecovirimat) label expansion decision](https://sec-api.dev/pdufa/tecovirimat) | SIGA |  | completed, approved | "NDA208627 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20211123, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22)) |
| May 18, 2022 | [TPOXX® (tecovirimat) FDA approval](https://sec-api.dev/pdufa/tecovirimat) | SIGA |  | completed, approved | "NDA214518 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220518, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214518%22)) |
| May 18, 2022 | [TPOXX® (tecovirimat) label expansion decision](https://sec-api.dev/pdufa/tecovirimat) | SIGA |  | completed, approved | "NDA208627 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220518, review_priority STANDARD; sponsor_name SIGA TECHNOLOGIES; product TPOXX (TECOVIRIMAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208627%22)) |
| March 11, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Twelve" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125008092/ef20045222_ex99-1.htm)) |
| May 8, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three Months Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125017954/ef20048574_ex99-1.htm)) |
| August 5, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125028821/ef20053161_ex99-1.htm)) |
| November 6, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125040775/ef20058429_ex99-1.htm)) |
| March 10, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Twelve" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126008782/ef20067458_ex99-1.htm)) |
| May 7, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126019538/ef20072552_ex99-1.htm)) |
| August 6, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126031672/ef20079446_ex99-1.htm)) |
| November 9, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126042783/ef20085184_ex99-1.htm)) |
| January 2027 | [TPOXX® (tecovirimat) primary completion](https://sec-api.dev/pdufa/tecovirimat) | SIGA | Smallpox | scheduled | "NCT04957485 (Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-01 (ESTIMATED); Lead Sponsor SIGA Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04957485)) |
| Jan to Apr 2027 | [TPOXX® (tecovirimat) topline data readout](https://sec-api.dev/pdufa/tecovirimat) | SIGA | Smallpox | scheduled | "NCT04957485 (Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-01 (ESTIMATED); Lead Sponsor SIGA Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04957485)) |

## Drugs

- [TPOXX® (tecovirimat)](https://sec-api.dev/pdufa/tecovirimat): Smallpox

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/siga/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SIGA catalysts: SIGA TECHNOLOGIES INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/siga/catalysts

```bibtex
@misc{secapidev_companies_siga_catalysts_20261116,
  title        = {SIGA catalysts: SIGA TECHNOLOGIES INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/siga/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_siga_catalysts_20261116","title":"SIGA catalysts: SIGA TECHNOLOGIES INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/siga/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
